A Taiwan-based VC with additional offices in USA has invested primarily in Taiwanese companies, but actively considers those based in the US as well. The firm invests primarily in therapeutics and digital health. The firm looks to be an active investor, and can help those companies looking to expand to the US. The firm invests early, in seed-early stage rounds, and generally makes a first investment of between $500K-1M.

The firm primarily invests in therapeutics and digital health, although will consider investing in medical devices or diagnostics if the company is exceptional. For therapeutics technology, the firm is agnostic to indication and will invest as early as proof of concept stage, although some animal data is preferable. For digital health companies, the firm is fairly flexible with regards to stage of development and will consider most healthcare-related or IoT technologies (e.g. smart hospital applications).

The firm looks for companies with great teams, whether they are experienced entrepreneurs or not. For companies based in Taiwan, the firm prefers to lead investments and take a board seat, playing an active role after investment. For US-based companies, the firm will generally co-invest and may recommend a partner to the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A medical device of a large Chinese pharmaceutical company has 226 affiliated companies with a total of over 8,000 employees, making over 3 billion revenue each year. The firm is interested in early-stage diagnostics, medical device and healthcare IT companies, but will also consider drugs in applicable cases.

The firm is generally interested in medical devices, diagnostics, and Digital healthcare companies with a preference for healthcare platform and CFDA approved companies. The firm will look at different stage companies that are investing in angel to pre-A, and IPO companies and provide investment consulting services to the firm

The firm invests globally but prefers companies with Chinese backgrounds. The firm strongly prefers companies with at least one Mandarin speaker in the management teams. The firm is willing to work with academic researchers or companies that are in very early stages and can provide supports in commercialization using the firm’s already-established internet platforms.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An R&D subsidiary of a Chinese pharmaceutical focuses on novel therapeutics. In the meantime, the firm is also responsible for sourcing global technology assets for the parent company. The firm is interested in Therapeutics and Healthcare IT opportunities. Fully funded by the parent company, the firm’s allocation size varies for the case to case, no upper limit, and in addition to investment the firm is also interested in co-development, in-licensing, and acquiring.

The firm is especially interested in Antibody therapeutics including new structure antibodies, Gene Therapy, CAR-T Therapy, Targeted Therapy, oncolytic virus therapy, and rare disease. Any combination of AI technology and therapeutics is preferred. For therapeutics, the firm focuses on products in pre-clinical and Phase I stage and will consider orphan indications.

The firm has no specific requirements for company and management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital firm with strong China expertise and global capabilities was founded in 2017. The firm discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs.

The firm currently has two funds: The first $115 million fund has been fully invested. The firm is raising another $115 million fund, which more than half are closed. The firm operates offices in USA and China.

The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.

The firm has no specific requirement for the company & management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global technology company is dedicated to crafting innovative optical and digital solutions in medical technologies; life sciences; industrial solutions; and cameras and audio products.

The company’s medical business works with health care professionals to combine their innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing with their skills to deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance quality of life for patients.

Throughout the company’s long history, the company has focused on being true to society and making people’s lives healthier, safer and more fulfilling. The company’s commitment to our purpose along with our major presence in hospitals around the world aligns with our goal to invest in future developments that will improve the experiences of providers and patients and transform Healthcare around the world.

The company is seeking partnerships and licensing relationships with early stage medical device startups worldwide. The company’s key areas of interest are endoscopes, laparoscopic devices, devices for minimally invasive surgery, and AI technologies across a wide range of specialties including ENT, gastrointestinal, respiratory, gynecology, and urology.

The company is interested in working with and supporting medical device companies with differentiated technology addressing unmet medical needs. An ideal partner would have an experienced management team with a proven track record of successful business development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Founded in 2011, a venture capital firm based in Southeast Asia makes Seed to Series B investments across several key sectors including healthcare, fintech, consumer, AI, and life science services. The firm manages $200 million, and is investing from its second fund. While the firm focuses on their home country, the firm is looking for opportunities worldwide and has recently made an investment in the USA.

The firm will consider a wide variety of life science opportunities. The firm’s past investments have included pharma supply chain, AI, and healthcare services.

The firm seeks a strong and experienced management team, with a focus on entrepreneurs from elite educational institutions.  The firm focuses on India and has a strong connection with major academic institutions in their country of origin, but looks worldwide for novel technology breakthroughs to invest in.  The firm has also launched a Unified Innovation and Entrepreneurship Platform to incubate new startups.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2015 and based in the USA also has a partner in China that can provide support to companies interested in China market entry, but companies do not need to have a China angle. The firm has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. Since its establishment, the firm has invested in over 30 companies and continues to actively seek life science investments, aiming to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies based in USA and China.

The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment.

The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.